ArticleThe Journal of experimental medicine2003
Complementary role of CD4+ T cells and secondary lymphoid tissues for cross-presentation of tumor antigen to CD8+ T cells.
Article in The Journal of experimental medicine, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 72 citations in OpenAlex.
- Cutting edge: persistence of transferred lymphocyte clonotypes correlates with cancer regression in patients receiving cell transfer therapy.Journal of immunology (Baltimore, Md. : 1950) · 2004Trial
- Balancing Intrinsic and Extrinsic Factors in CD8Immune network · 2026Review
- CD8Immunity · 2023Article
- An oral cancer vaccine using aMolecular therapy oncolytics · 2021Article
- Blood Vessels and Peripheral Nerves as Key Players in Cancer Progression and Therapy Resistance.Cancers · 2021Review
- Induced Regulatory T Cells Superimpose Their Suppressive Capacity with Effector T Cells in Lymph NodesFrontiers in immunology · 2017Article
- Unique CD8+ T Cell-Mediated Immune Responses Primed in the Liver.Transplantation · 2016Article
- Rational bases for the use of the Immunoscore in routine clinical settings as a prognostic and predictive biomarker in cancer patients.International immunology · 2016Review
- Article
- Microenvironment of tumor-draining lymph nodes: opportunities for liposome-based targeted therapy.International journal of molecular sciences · 2014Review
- Effective cancer vaccine platform based on attenuated salmonella and a type III secretion system.Cancer research · 2014Article
- Tumor cells, rather than dendritic cells, deliver antigen to the lymph node for cross-presentation.Oncoimmunology · 2012Article
- Carboxymethylpachymaran enhances immunologic function of dendritic cells cultured in two kinds of hepatoma carcinoma cell line's supernatant via nuclear factor κ B/Rel pathway.Chinese journal of integrative medicine · 2012Article
- Bystander killing of cancer requires the cooperation of CD4(+) and CD8(+) T cells during the effector phase.The Journal of experimental medicine · 2010Article
- Novel cancer vaccine based on genes of Salmonella pathogenicity island 2.International journal of cancer · 2010Article
- Effect of B7.1 costimulation on T-cell based immunity against TAP-negative cancer can be facilitated by TAP1 expression.PloS one · 2009Article
- In situ expression of IFN-gamma-inducible T cell alpha chemoattractant in breast cancer mounts an enhanced specific anti-tumor immunity which leads to tumor regression.Cancer immunology, immunotherapy : CII · 2007Article
- Targeting the primary tumor to generate CTL for the effective eradication of spontaneous metastases.Journal of immunology (Baltimore, Md. : 1950) · 2007Article
- Indoleamine 2,3-dioxygenase and tumor-induced tolerance.The Journal of clinical investigation · 2007Review
- Endoglin (CD105) is a target for an oral DNA vaccine against breast cancer.Cancer immunology, immunotherapy : CII · 2006Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
MHC class I-restricted tumor antigens can be presented to CD8+ T cells by two distinct pathways: via direct and indirect presentation. The relative contribution of these two pathways toward the initial activation of tumor antigen-specific CD8+ T cells and their subsequent tumor rejection is still vigorously debated. Using a tumor model able to dissect the relative contributions of direct and indirect presentation, we show unequivocally the inefficiency of direct presentation and the essential requirement of indirect presentation for the priming of naive tumor antigen-specific T cells leading to tumor rejection. Moreover, we characterize the essential environment under which indirect presentation occurs, and find efficient cross-priming of tumor-specific CD8+ T cells in the complete absence of secondary lymphoid tissues. The independence of this process from local lymph nodes is compromised, however, in the absence of CD4+ T cell help. Therefore, our paper demonstrates that effective immune protection against tumors requires the cross-priming of CD8+ T cells under conditions that require either CD4+ T cell help, or draining lymph nodes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.